Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLI-03A
- Development stage
- Unknown
- Lead developer
- DNAtrix
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
VLI-03A is an experimental therapeutic candidate for the treatment of Hepatitis C, originally developed by VectorLogics before its merger with DNAtrix in 2011. DNAtrix is a biotechnology company primarily focused on developing oncolytic viruses, such as tasadenoturev, for the treatment of cancer. VLI-03A is considered a legacy asset within the DNAtrix portfolio, and there is limited public information regarding its specific modality, though it likely utilizes the company's expertise in adenoviral vectors. As of current records, the drug does not appear to be in active clinical development, with its status generally categorized as unknown or pending in pharmaceutical pipeline databases.
Beyond the preview
Go deeper on VLI-03A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLI-03A.